FogPharma is a company developing HeliconTM peptides, a new drug modality that combines the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. This new class of drugs aims to overcome the limitations of current precision medicines and achieve universal druggability. HeliconTM peptides have the potential to quickly and effectively treat a wide range of human diseases.